NZ331370A - Crystal modification B and C of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and use thereof - Google Patents

Crystal modification B and C of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and use thereof

Info

Publication number
NZ331370A
NZ331370A NZ331370A NZ33137098A NZ331370A NZ 331370 A NZ331370 A NZ 331370A NZ 331370 A NZ331370 A NZ 331370A NZ 33137098 A NZ33137098 A NZ 33137098A NZ 331370 A NZ331370 A NZ 331370A
Authority
NZ
New Zealand
Prior art keywords
difluorobenzyl
carboxamide
triazole
crystal modification
crystal
Prior art date
Application number
NZ331370A
Other languages
English (en)
Inventor
Robert Portmann
Urs Christoph Hofmeier
Andreas Burkhard
Walter Scherrer
Martin Szelagiewicz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4209650&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ331370(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NZ331370A publication Critical patent/NZ331370A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NZ331370A 1997-06-10 1998-06-08 Crystal modification B and C of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and use thereof NZ331370A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH140497 1997-06-10
PCT/EP1998/003428 WO1998056773A1 (en) 1997-06-10 1998-06-08 Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide and its use as antiepileptic

Publications (1)

Publication Number Publication Date
NZ331370A true NZ331370A (en) 2000-08-25

Family

ID=4209650

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ331370A NZ331370A (en) 1997-06-10 1998-06-08 Crystal modification B and C of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and use thereof
NZ331371A NZ331371A (en) 1997-06-10 1998-06-08 Crystal modification of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ331371A NZ331371A (en) 1997-06-10 1998-06-08 Crystal modification of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and use thereof

Country Status (36)

Country Link
US (6) US6740669B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (2) EP0994864B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (2) JP3672575B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (2) KR100409168B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (3) CN1132820C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (4) AR012945A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (2) ATE232852T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (2) AU725528B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (2) BR9804946A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (3) CA2256015C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CO (2) CO4940448A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (1) CY2007014I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (2) CZ292481B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (3) DE69813560T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (2) DK0994864T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (2) ES2192779T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR07C0037I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (2) HU226107B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ID (2) ID27660A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (2) IL125732A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (1) LU91345I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (2) MY125854A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL300284I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (2) NO329314B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (2) NZ331370A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PE (2) PE79799A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (2) PL191943B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT994864E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (2) RU2194041C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (2) SI0994863T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SK (2) SK283685B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TR (2) TR199801630T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (2) TW403740B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UY (1) UY25844A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (2) WO1998056772A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (2) ZA984967B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW403740B (en) 1997-06-10 2000-09-01 Novartis Ag Novel crystal modifications of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide
WO2003101991A1 (en) * 2002-05-31 2003-12-11 Schering Corporation Xanthine phosphodiesterase v inhibitor polymorphs
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
US7875284B2 (en) * 2006-03-10 2011-01-25 Cook Incorporated Methods of manufacturing and modifying taxane coatings for implantable medical devices
US20090069390A1 (en) * 2007-09-12 2009-03-12 Protia, Llc Deuterium-enriched rufinamide
US8183269B2 (en) 2008-10-13 2012-05-22 Cipla Limited Process for the preparation of rufinamide
CN101768124B (zh) * 2008-12-30 2012-01-04 北京本草天源药物研究院 一种药物晶体及其制备方法和用途
IT1395736B1 (it) * 2009-08-04 2012-10-19 Dipharma Francis Srl Forme cristalline di rufinamide
AU2010290049B2 (en) * 2009-09-04 2013-09-19 Tactical Therapeutics, Inc Novel compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulations
EP2465853A1 (en) * 2010-12-14 2012-06-20 Laboratorios Lesvi, S.L. Polymorph of rufinamide and process for obtaining it
JP2013525413A (ja) * 2010-04-30 2013-06-20 ラボラトリオス レスヴィ，エス．エル． ルフィナマイド中間体の改良された製造方法
ITMI20110718A1 (it) 2011-04-29 2012-10-30 Dipharma Francis Srl Procedimento per la purificazione di rufinamide
US10206874B2 (en) 2012-07-20 2019-02-19 Hetero Research Foundation Rufinamide solid dispersion
WO2021099481A1 (en) 2019-11-20 2021-05-27 Medichem, S.A. Solid composition containing rufinamide

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3992378A (en) 1973-12-26 1976-11-16 Eli Lilly And Company Fluoralkyl quinoxadinediones
US4156734A (en) 1976-02-13 1979-05-29 Merck & Co., Inc. Antihypertensive compositions containing an aryl-substituted alanine azo and an arylhydrazino-propionic acid
GB1511195A (en) 1976-10-18 1978-05-17 Ici America Inc Triazole derivatives
US4536518A (en) 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
US4346097A (en) * 1980-09-30 1982-08-24 Warner-Lambert Company Method for treating convulsions with pyrazole-4-carboxamide derivatives
US4789680A (en) * 1982-12-23 1988-12-06 Ciba-Geigy Corporation Aralkyltriazole compounds
FI834666A7 (fi) 1982-12-23 1984-06-24 Ciba Geigy Ag Foerfarande foer framstaellning av nya aralkyltriazolfoereningar.
US4511572A (en) * 1983-03-18 1985-04-16 The University Of Kentucky Research Foundation Triazoline anticonvulsant drugs
FI93544C (fi) * 1985-04-18 1995-04-25 Ciba Geigy Ag Menetelmä fluorattujen, antikonvulsiivisesti vaikuttavien 1-bentsyyli-1H-1,2,3-triatsoliyhdisteiden valmistamiseksi
CA2002864C (en) 1988-11-29 1999-11-16 Eddy J. E. Freyne (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives
JPH02214504A (ja) 1989-02-15 1990-08-27 Nissan Chem Ind Ltd 光学活性キノキサリン化合物の晶析法
JPH04506967A (ja) 1989-07-27 1992-12-03 ジー．ディー．サール　アンド　カンパニー 高血圧症治療用腎選択性生成物
IL96507A0 (en) 1989-12-08 1991-08-16 Merck & Co Inc Nitrogen-containing spirocycles and pharmaceutical compositions containing them
AU656154B2 (en) 1990-11-06 1995-01-27 Astellas Pharma Inc. Fused pyrazine derivative
JP2753911B2 (ja) 1991-12-06 1998-05-20 キッセイ薬品工業株式会社 Ｎ−ｔｅｒｔ−ブチル−１−メチル−３，３−ジフェニルプロピルアミン塩酸塩の結晶多形およびその製造方法
DE4217952A1 (de) 1992-05-30 1993-12-02 Basf Ag Chinoxalin-2,3(1H,4H)-dione
US5248699A (en) 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
US5631373A (en) 1993-11-05 1997-05-20 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones
GB9418443D0 (en) 1994-09-13 1994-11-02 Pfizer Ltd Therapeutic agents
GB9419318D0 (en) 1994-09-24 1994-11-09 Pfizer Ltd Therapeutic agents
DE69609314T2 (de) 1995-02-22 2001-06-13 Aventis Pharma Ltd., Tokio/Tokyo Amorph piretanide, polymorphe davon, verfahren zur dessen herstellung und ihre verwendung
SI0918758T1 (en) * 1996-07-11 2002-10-31 Novartis Ag Process for preparing 1-substituted 4-cyano-1,2,3-triazoles
TW403740B (en) * 1997-06-10 2000-09-01 Novartis Ag Novel crystal modifications of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide

Also Published As

Publication number Publication date
US20010037029A1 (en) 2001-11-01
CY2007014I1 (el) 2009-11-04
WO1998056772A1 (en) 1998-12-17
IL125732A (en) 2002-12-01
TR199801630T1 (xx) 1999-06-21
CN1259127A (zh) 2000-07-05
PL191943B1 (pl) 2006-07-31
JP3672574B2 (ja) 2005-07-20
US20040167186A1 (en) 2004-08-26
CO4940448A1 (es) 2000-07-24
CY2007014I2 (el) 2009-11-04
ID27660A (id) 2001-04-19
ZA984966B (en) 1999-01-11
SI0994864T1 (en) 2003-10-31
CN1132820C (zh) 2003-12-31
PL330798A1 (en) 1999-06-07
US6740669B1 (en) 2004-05-25
NO983667L (no) 1998-12-17
KR100409168B1 (ko) 2004-01-31
ZA984967B (en) 1999-01-11
RU2194041C2 (ru) 2002-12-10
ID21014A (id) 1999-04-08
LU91345I2 (fr) 2007-09-04
KR19990087836A (ko) 1999-12-27
MY120156A (en) 2005-09-30
DE69813560D1 (de) 2003-05-22
CN1159300C (zh) 2004-07-28
AU8437198A (en) 1998-12-30
DE122007000051I2 (de) 2009-02-19
MY125854A (en) 2006-08-30
CZ253398A3 (cs) 1999-04-14
PE80999A1 (es) 1999-09-06
DE122007000051I1 (de) 2007-11-08
US20100310655A1 (en) 2010-12-09
DK0994864T3 (da) 2003-07-21
US20030125568A1 (en) 2003-07-03
ATE237599T1 (de) 2003-05-15
US20060116520A1 (en) 2006-06-01
ES2192779T3 (es) 2003-10-16
HU226107B1 (en) 2008-04-28
RU2198167C2 (ru) 2003-02-10
TW526195B (en) 2003-04-01
DE69811500T2 (de) 2004-04-01
DE69811500D1 (de) 2003-03-27
EP0994864B1 (en) 2003-04-16
HK1028242A1 (en) 2001-02-09
CZ292481B6 (cs) 2003-09-17
JP3672575B2 (ja) 2005-07-20
HU225153B1 (en) 2006-07-28
DK0994863T3 (da) 2003-05-26
ES2197485T3 (es) 2004-01-01
KR100425656B1 (ko) 2004-05-17
NO329314B1 (no) 2010-09-27
CZ292260B6 (cs) 2003-08-13
US7750028B2 (en) 2010-07-06
LU91345I9 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2018-12-31
AR012945A1 (es) 2000-11-22
NO983666L (no) 1998-12-17
HUP0002113A3 (en) 2002-09-30
JP2000516259A (ja) 2000-12-05
HUP0000798A2 (hu) 2000-10-30
AU8437298A (en) 1998-12-30
SK109498A3 (en) 1998-12-02
HK1028031A1 (en) 2001-02-02
ATE232852T1 (de) 2003-03-15
PT994864E (pt) 2003-07-31
TW403740B (en) 2000-09-01
EP0994864A1 (en) 2000-04-26
PL330764A1 (en) 1999-05-24
NZ331371A (en) 2000-08-25
CN1572789A (zh) 2005-02-02
NL300284I2 (nl) 2007-11-01
KR19990087835A (ko) 1999-12-27
CA2614926A1 (en) 1998-12-17
US8076362B2 (en) 2011-12-13
AU725517B2 (en) 2000-10-12
CA2256013A1 (en) 1998-12-17
UY25844A1 (es) 2001-08-27
NO329315B1 (no) 2010-09-27
AR061004A2 (es) 2008-07-30
HUP0000798A3 (en) 2000-10-30
IL125732A0 (en) 1999-04-11
BR9804946A (pt) 1999-08-24
US6455556B2 (en) 2002-09-24
HUP0002113A2 (hu) 2001-02-28
EP0994863B1 (en) 2003-02-19
IL125733A0 (en) 1999-04-11
SK283685B6 (sk) 2003-12-02
BR9804947A (pt) 1999-08-24
AR012946A1 (es) 2000-11-22
CZ253498A3 (cs) 1999-04-14
SK283734B6 (sk) 2003-12-02
WO1998056773A1 (en) 1998-12-17
NO983666D0 (no) 1998-08-11
FR07C0037I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2007-08-17
CN1298708C (zh) 2007-02-07
CA2256015A1 (en) 1998-12-17
PE79799A1 (es) 1999-09-03
AU725528B2 (en) 2000-10-12
IL125733A (en) 2002-12-01
SK109398A3 (en) 1998-12-02
NL300284I1 (nl) 2007-10-01
NO983667D0 (no) 1998-08-11
TR199801631T1 (xx) 1999-06-21
CA2614926C (en) 2010-02-09
AR061005A2 (es) 2008-07-30
CA2256013C (en) 2007-10-16
HK1028241A1 (en) 2001-02-09
CN1217716A (zh) 1999-05-26
FR07C0037I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2008-05-16
SI0994863T1 (en) 2003-08-31
CO4940452A1 (es) 2000-07-24
DE69813560T2 (de) 2004-02-05
PL192114B1 (pl) 2006-08-31
EP0994863A1 (en) 2000-04-26
JP2000516258A (ja) 2000-12-05
CA2256015C (en) 2008-06-03

Similar Documents

Publication Publication Date Title
NL300284I1 (nl) Kristalmodificatie van 1-(2,6-difluorbenzyl)1H-1,2,3-triazool-4-carboxamide en de toepassing daarvanals anti-epilepticum.
PT741716E (pt) Analogos de delta 12,13-iso-taxol sua utilizacao anti-neoplasica e composicoes farmaceuticas que os contem
MY129541A (en) Substituded 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators
BG103399A (en) New heterocycle-substituted benzamides and their application for the treatment of diseases
AU6613896A (en) Chemical compounds
BG105783A (en) Triazole compounds with dopamine-d3-receptor affinity
IL124674A0 (en) Piperazine derivatives pharmaceutical compositions containing the same and use thereof
NZ237023A (en) 17beta-substituted-4-aza-5alpha-androstan-3-ones and pharmaceutical compositions
ITMI931780A1 (it) Tropil 7-azaindolil-3-carbossiamidi
CA2371012A1 (en) 4-(1h-pyrrol-1-yl) imidazoles
AU2672895A (en) (a)-annelated pyrrole derivatives and pharmaceutical use thereof
HUT73759A (en) Herbicidal substituted 1-phenyl or 1-pyridinyl benzotriazoles
NO971997D0 (no) Bruk av immunmodulerende midler
GB9907571D0 (en) Compounds
GR3023427T3 (en) Heteroarylmethylbenzols aromatase inhibitors
CZ157795A3 (en) Pharmaceutical preparations for treating prostatitis
TW330933B (en) Furanoeremophilane and eremophilanolide sesquiterpenes for treatment of diabetes
EP0828493A4 (en) 4.4-DISUBSTITUTED CYCLOHEXANE-1-OL MONOMERS AND RELATED COMPOUNDS
AU4944899A (en) New pharmaceutically active compounds
HRP950271A2 (en) New peptide active substance and the production thereof
AU3744100A (en) Bicyclo(3.3.1)nonenes useful for the treatment of diabetes
MY116562A (en) Fungicidal active compound combinations
HUP9801596A3 (en) Use of azole compounds for preparing pharmaceutical compositions useful for the treatment of fungal infections, new azole derivatives and pharmaceutical compositions containing them
AU2083995A (en) Novel triazole derivative and antimycotic agent containing the same as active ingredient
HK1009392A (en) 4.4-(disubstituted)cyclohexan-1-ols-monomers and related compounds

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
EXPY Patent expired